Glenmark Pharma Received Approval For Tacrolimus Capsules Thus Expand Its Presence In The Global Tacrolimus Market
Growing organ transplant procedures around the globe are driving the growth of the Tacrolimus market. It is mostly used as an immunosuppressant after organ transplant procedures application. This is expected to increase organ transplant procedures. Moreover, improvement in the transplantation procedure such as feasibility and a better understanding of immunology is again expected to foster the growth of the market. For instance, in February 2021, India-based generics makers Biocon and Lupin have both launched generic tacrolimus capsules in the US. It had launched tacrolimus capsules at doses of 0.5 mg, 1 mg, and 5 mg.
1. In June 2020, Sandoz announced
the launch of once-daily generic tacrolimus capsules known as Dailiport® in
Germany, the UK, Netherlands, Finland, Sweden, Estonia, Latvia, Slovakia, and
as Conferoport® in Italy and Spain
2. In March 2019, Astellas announced
the launch of PROGRAF® Granules (tacrolimus for oral suspension) in the United
States. PROGRAF is used in combination with other immunosuppressants to help
prevent organ rejection in people who have had a liver, heart, or kidney transplant.
3. In November 2020, Glenmark Pharma
announced that it has received final approval from the US health regulator for
Tacrolimus capsules, used as immuno-suppressant.
4. In October 2020, Aequus
Pharmaceuticals Inc. announced that it has agreed to an extension of terms for
its promotional service agreement with Sandoz Canada Inc. (“Sandoz”) on
tacrolimus immediate-release (“Tacrolimus IR”) to December 31st, 2021
5. In June 2020, TFF
Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration
(FDA) has granted orphan drug designation to Tacrolimus Inhalation Powder for
prophylaxis of lung allograft rejection
North America is expected to lead the global Tacrolimus market in the near future and this is attributed to the high number of organ transplant procedures in the region. In 2019, a total of 3,014 organ transplant procedures were performed in Canada, according to the latest data from the Canadian Organ Replacement Register (CORR) — a pan-Canadian information system for organ failure in Canada. The need for renal replacement therapy in Canada is growing: the rate of new patients starting therapy increased 1.6% a year on average between 2010 and 2019.
Tacrolimus
is a type of immunosuppressant which is majorly used after organ transplant
procedures in order to prevent organ rejection. It inhibits the initiation of
serine-threonine phosphatase, calcineurin, in T lymphocytes. This suppresses
the activation of T lymphocytes and subsequent generation of cytotoxic
lymphocytes hence suppresses the process of organ rejection.
Comments
Post a Comment